Prognostic factors in muscle-infiltrating bladder cancer (MIBC) treated with an organ-sparing treatment with concurrent gemcitabine (GEM) and radiotherapy (XRT): Results of a patient-based cumulative analysis of seven phase I-II trials.

Abstract

e15529 Background: GEM is a highly effective radiosensitiser and has been combined with XRT in MIBC after transurethral resection to achieve bladder preservation. Several phase I-II trials were con...